Company Overview and News

 
Deals of the day-Mergers and acquisitions

2018-05-23 reuters
May 23 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1000 GMT on Wednesday:

 
GUAA / Guaranty Bancorp, Inc. 8-K (Prospectus)

2018-05-23 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION

 
GUAA / Guaranty Bancorp, Inc. 8-K (Current Report)

2018-05-23 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION

 
GUAA / Guaranty Bancorp, Inc. 425 (Prospectus)

2018-05-23 sec.gov
Filed by Guaranty Ban

 
Independent Bank to buy Guaranty Bancorp for about $1 bln

2018-05-22 reuters
(Reuters) - Independent Bank Group Inc said on Tuesday it would buy Guaranty Bancorp for about $1 billion to expand its operations in the state of Colorado.

 
Independent Bank Group, Inc. to Acquire Guaranty Bancorp

2018-05-22 globenewswire
MCKINNEY, Texas and DENVER, May 22, 2018 (GLOBE NEWSWIRE) -- Independent Bank Group, Inc. (NASDAQ:IBTX), the holding company for Independent Bank, and Guaranty Bancorp (NASDAQ:GBNK), the holding company for Guaranty Bank and Trust Company, today jointly announced the signing of a definitive merger agreement pursuant to which Guaranty Bancorp will merge with and into Independent Bank Group in an all-stock transaction.

 
GUAA / Guaranty Bancorp, Inc. 8-K (Current Report)

2018-05-08 sec.gov
Q2 2018 Dividend 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

 
GUAA / Guaranty Bancorp, Inc. 10-Q (Quarterly Report)

2018-05-01 sec.gov
10-Q 20180331 Q1 Table of Contents UNITED STATES

 
GUAA / Guaranty Bancorp, Inc. 8-K (Current Report)

2018-04-18 sec.gov
8K for Q1 2018 Earnings Release  UNITED STATES SECURITIES AND EXCHANGE COMMISSION

 
GUAA / Guaranty Bancorp, Inc. DEF 14A

2018-03-23 sec.gov
2018 Proxy Statement Table of Contents

 
GUAA / Guaranty Bancorp, Inc. 10-K (Annual Report)

2018-02-28 sec.gov
10-K 20171231 Table of Contents

 
GUAA / Guaranty Bancorp, Inc. 144

2018-02-13 sec.gov
  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933 OMB APPROVAL OMB Number:  3235-0101 Expires: May 31, 2017 Estimated average burden hours per response . . . 1.00 SEC USE ONLY DOCUMENT SEQUENCE NO.   CUSIP NUMBER ATTENTION: Transmit for filing 3 copies of this form concurrently with either placing an order with a broker to execute sale or executing a sale directly with a m

 
GUAA / Guaranty Bancorp, Inc. 144

2018-02-13 sec.gov
  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933 OMB APPROVAL OMB Number:  3235-0101 Expires: May 31, 2017 Estimated average burden hours per response . . . 1.00 SEC USE ONLY DOCUMENT SEQUENCE NO.   CUSIP NUMBER ATTENTION: Transmit for filing 3 copies of this form concurrently with either placing an order with a broker to execute sale or executing a sale directly with a m

 
GUAA / Guaranty Bancorp, Inc. 144

2018-02-13 sec.gov
  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933 OMB APPROVAL OMB Number:  3235-0101 Expires: May 31, 2017 Estimated average burden hours per response . . . 1.00 SEC USE ONLY DOCUMENT SEQUENCE NO.   CUSIP NUMBER ATTENTION: Transmit for filing 3 copies of this form concurrently with either placing an order with a broker to execute sale or executing a sale directly with a m

 
GUAA / Guaranty Bancorp, Inc. 144

2018-02-13 sec.gov
  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933 OMB APPROVAL OMB Number:  3235-0101 Expires: May 31, 2017 Estimated average burden hours per response . . . 1.00 SEC USE ONLY DOCUMENT SEQUENCE NO.   CUSIP NUMBER ATTENTION: Transmit for filing 3 copies of this form concurrently with either placing an order with a broker to execute sale or executing a sale directly with a m

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...